Human platelet activation is associated with, and regulated by, the phosphorylation of a number of proteins. Recently, attention has been focused on tyrosine phosphorylation of proteins and their function in platelet activation. Here vanadate, an inhibitor of tyrosine phosphohydrolase, was used to examine the role that tyrosine phosphorylation plays in platelet activation. Vanadate (7.5 to 100 pmol/L) stimulated the dose-dependent aggregation of saponin-permeabilized, but not intact, platelets. Electron-microscopic studies indicated small degranulated aggregates. Vanadate-induced aggregation was inhibited by pretreatment with prostacyclin (1 to 10 nmol/L), genistein (1 to 10 pg/mL), aspirin (1 00 pmol/L), or BW755C (80 pmol/L). Aggregation was associated with the aspirin-sensitive formation of [32P]-phosphatidic acid and the phosphorylation of platelet proteins, notably pleckstrin and myosin light chain. Immunoblotting studies indicated that vanadate caused the tyrosine phosphorylation of proteins of approximate molecular HE IMPORTANCE of protein phosphorylation on ty-T rosine rather than serine or threonine residues was first realized after the discovery that several oncogenes encoded for tyrosine kinases. There are two classes of tyrosine kinases: growth factor receptors (such as those for platelet-derived growth factor [PDGF] and epidermal growth factor [EGF]'), and those with unknown functions (tyrosine kinases that lack transmembrane domains but that are associated with membranes by a myristic acid link*). Platelets are non-nucleated cells that have abundant levels of nonreceptor tyrosine kinases such as pp60'"" and p6OfYn and that exhibit phosphotyrosine pho~phorylation."~ Recently, phosphotyrosine phosphatases (PTPases), which are potently inhibited by vanadate," have also been implicated in signal transduction. I '-I3 There have been few studies addressing the platelet PTPases. Smilowitz et all4 reported the presence of multiple forms of vanadate-sensitive PTPases and raised the possibility that agonists may stimulate platelets by inhibiting one or more of these enzymes. A study in electropermeabilized platelets reported vanadate-induced tyrosine phosphorylation of platelet proteins of molecular weights 38 and 50 Kd and speculated that the SO-Kd platelet protein may play a role in exocyto~is.'~ Platelet aggregation was reported after the co-addition of vanadate and hydrogen peroxide (H2O2) and aggregation was associated with tyrosine phosphorylation, as monitored by Western b l~t t i n g . '~. '~ Studies in neutrophils'* and in HL60 cells19 have shown that vanadate stimulates tyrosine phosphorylation and the respiratory burst in a parallel manner. Similarly, in mouse pancreatic B cells, vanadate potentiated insulin release associated with a complex action on phospholipase C.*" These reports indicate a role for PTPases in the process of stimulus-response coupling. In the present study we have examined the temporal relationship between this phosphatase activity and other biochemical events associated with platelet activation in order to elucidate the site at which phosphotyrosine regulates platelet activation. In contrast to previous platelet studies, we have used saponin-permeabilizati~n~~~~~ to introduce vanadate into the cell. This technique allows the introduction of nonpermeable or semipermeable mole- These findings show that vanadate stimulates platelets by promoting arachidonic acid release from phospholipids. Tyrosine phosphorylation, potentially of the 80-or 90-Kd proteins, may regulate a platelet phospholipase A2. The released arachidonic acid was converted to thromboxane A2 that produced secondary effects such as phospholipase C activation, protein phosphorylation, and aggregation, and was associated with the tyrosine phosphorylation of the 26-, 29-, 32-, 40-, and 42-Kd proteins.
Human platelet activation is associated with, and regulated by, the phosphorylation of a number of proteins. Recently, attention has been focused on tyrosine phosphorylation of proteins and their function in platelet activation. Here vanadate, an inhibitor of tyrosine phosphohydrolase, was used to examine the role that tyrosine phosphorylation plays in platelet activation. Vanadate (7.5 to 100 pmol/L) stimulated the dose-dependent aggregation of saponin-permeabilized, but not intact, platelets. Electron-microscopic studies indicated small degranulated aggregates. Vanadate-induced aggregation was inhibited by pretreatment with prostacyclin (1 to 10 nmol/L), genistein (1 to 10 pg/mL), aspirin (1 00 pmol/L), or BW755C (80 pmol/L). Aggregation was associated with the aspirin-sensitive formation of [32P]-phosphatidic acid and the phosphorylation of platelet proteins, notably pleckstrin and myosin light chain. Immunoblotting studies indicated that vanadate caused the tyrosine phosphorylation of proteins of approximate molecular HE IMPORTANCE of protein phosphorylation on ty-T rosine rather than serine or threonine residues was first realized after the discovery that several oncogenes encoded for tyrosine kinases. There are two classes of tyrosine kinases: growth factor receptors (such as those for platelet-derived growth factor [PDGF] and epidermal growth factor [EGF]'), and those with unknown functions (tyrosine kinases that lack transmembrane domains but that are associated with membranes by a myristic acid link*). Platelets are non-nucleated cells that have abundant levels of nonreceptor tyrosine kinases such as pp60'"" and p6OfYn and that exhibit phosphotyrosine pho~phorylation."~ Recently, phosphotyrosine phosphatases (PTPases), which are potently inhibited by vanadate," have also been implicated in signal transduction. I '-I3 There have been few studies addressing the platelet PTPases. Smilowitz et all4 reported the presence of multiple forms of vanadate-sensitive PTPases and raised the possibility that agonists may stimulate platelets by inhibiting one or more of these enzymes. A study in electropermeabilized platelets reported vanadate-induced tyrosine phosphorylation of platelet proteins of molecular weights 38 and 50 Kd and speculated that the SO-Kd platelet protein may play a role in exocyto~is.'~ Platelet aggregation was reported after the co-addition of vanadate and hydrogen peroxide (H2O2) and aggregation was associated with tyrosine phosphorylation, as monitored by Western b l~t t i n g . '~. '~ Studies in neutrophils'* and in HL60 cells19 have shown that vanadate stimulates tyrosine phosphorylation and the respiratory burst in a parallel manner. Similarly, in mouse pancreatic B cells, vanadate potentiated insulin release associated with a complex action on phospholipase C.*"
These reports indicate a role for PTPases in the process of stimulus-response coupling. In the present study we have examined the temporal relationship between this phosphatase activity and other biochemical events associated with platelet activation in order to elucidate the site at which phosphotyrosine regulates platelet activation. In contrast to previous platelet studies, we have used saponin-permeabilizati~n~~~~~ to introduce vanadate into the cell. This technique allows the introduction of nonpermeable or semipermeable mole- cules to the platelet cytoplasm without the invasive effects of electropermeabilization or the complications potentially associated with the addition of Hz02 to cells. Thus, the cytosolic concentration of vanadate can be rapidly manipulated to a level consistent with PTPase inhibition and an acute response monitored without relying on passive diffusion into the platelets. interfere with platelet function within the previous 2 weeks, was collected into acid-citrate dextrose anticoagulant (3.8 mmol/L citric acid, 7.5 mmol/L trisodium citrate, 125 mmol/L dextrose; 1.9 mL anticoagulant per 8. I mL whole blood). Platelet-rich plasma (PRP) was obtained by centrifugation at 800g for 5 minutes. Plasma-free platelet suspensions were prepared by centrifugation (800g for 10 minutes) and the platelet pellet was resuspended in a high-citrate washing buffer. 22 The platelets were pelleted by centrifugation (800g for IO minutes) and the resultant pellet resuspended in a high-potassium buffer that resembles the cytoplasm. 22 Platelets were placed in an aggregometer cuvette and stirred with IO to 14 j&mL saponin for 2 minutes before the addition of vanadate. Aggregation was monitored photometrically with continuous stirring at 37°C in a Payton dual-channel aggregometer (Payton Associates, Scarborough, Ontario, Canada). Saponin alone did not cause aggregation and its concentration was carefully titered in each experiment to avoid cell lysis.
MATERIALS AND METHODS

Materials
PRP was centrifuged (800g for I O minutes). The resultant pellet was then resuspended in I mL of platelet poor plasma (PPP) and labeled with 100 pCi/mL [3ZP]-or&hophosphate for 90 minutes at 37°C. The platelets were washed by centrifugation (800g for 10 minutes) and prepared for aggregation as described above. At the appropriate time, aggregation was terminated and the phospholipids extracted,24 separated by thin-layer chr~matography;~ autoradiographed, and quantified by radiochromatogram scanning. 26 Under the experimental conditions used the [32P]-orthophosphate is preferentially incorporated into the highly metabolically active phos-
Platelet aggregation.
Phosphoinositide metabolism.
phoinositides rather than the more abundant phosphatidylcholine and the formation of ["PI-phosphatidic acid reflects the effects of the phosphoinositide-specific phospholipase C rather than nonspecific phospholipase C or phospholipase D. Therefore, [32P]-phosphatidic acid was monitored as an indirect index of phosphoinositide metab01ism.~' Platelets were labeled with 1 mCi/mL [32P]-orthophosphate for 60 minutes, washed, and aggregation was performed as outlined above for phosphoinositide metabolism. The samples were denatured by boiling for 3 minutes in a solubilizing solution (2% sodium dodecyl sulfate [SDS], 2% 8-mercaptoethanol, 10% glycerol, I mmol/L EDTA, 4 mmol/L EGTA, 0.01% bromophenol blue, I50 mmol/L Tris HCI; pH 6.8). Proteins were separated on a 10% polyacrylamide/SDS vertical slab gel that was dried and autoradiographed as previously described?"
Permeabilized platelets were prepared and aggregation studies performed as described above. The samples were then denatured by boiling in the solubilization buffer. The proteins were separated on a 10% polyacrylamide/SDS vertical slab gel and then transferred to nitrocellulose at 100 V for I hour at 15°C. 
Immunoblotting.
For personal use only. on November 11, 2017 . by guest www.bloodjournal.org From Arachidonic acid release and thromboxane (Tx) production. PRP was centrifuged (8OOg for 10 minutes) and the resultant pellet was resuspended in 1 mL of PPP and labeled with 1 pCi/mL ['HI-arachidonic acid for 60 minutes at 37°C. The platelets were washed by centrifugation (8OOg for 10 minutes). The platelet pellet was then resuspended in the above high-citrate washing buffer that was supplemented with 0.3% fatty-acid-free bovine serum albumin (BSA). The platelets were further pelleted by centrifugation (800g for IO minutes) and finally resuspended in the above high-potassium buffer, also supplemented with 0.3% fatty-acid-free BSA. Aggregation was performed as above and terminated by immersing the entire sample into liquid nitrogen. The arachidonate metabolites were extracted in ethyl acetate and separated by thin-layer chromatography with a mobile phase of ch1oroform:methanol:acetic acid:water (90.08.0: l .00.8)
as previously described.26 Spots corresponding to arachidonic acid and TxB,, the stable metabolite of the active TxA2, were scraped and quantified by liquid scintillation counting.
Permeabilized platelets were prepared as for aggregometry as outlined above. The platelets were then fixed by Electron microscopy. the addition of an equal volume of 0. I% glutaraldehyde in White's saline?9 postfixed, stained, dehydrated, and embedded in Epon araldite as previously described." Thin sections were stained with lead citrate and examined on a Philips EM400 electron microscope (Eindhoven, The Netherlands).
RESULTS
Efects of vanadate on platelet aggregation.
T h e addition of vanadate (7.5 to 100 pmol/L) to saponin-permeabilized, but not to intact (Fig IA) , human platelets caused aggregation in a concentration-dependent manner (Fig 1 B) , indicating the intracellular nature of the vanadate substrate. Vanadate has been reported to inhibit ATPases, notably the Na+/K+ ATPase.3' However, ouabain (100 pmol/L), another Na+/ K+ ATPase inhibitor, failed to stimulate aggregation i n intact or permeabilized platelets (data not shown).
T h e concentration of vanadate (100 pmol/L) shown to cause maximal platelet aggregation (Fig 1 B) inhibited by pretreatment with prostacyclin at concentrations ( 1 to 10 nmol/L) consistent with adenylate cyclase activation (Fig 2A) , or with genistein (1 to 30 pg/mL; Fig 2B) , a tyrosine kinase inhibitor32 that has recently been shown also to antagonize the Tx r e~e p t o r .~~,~~ In the latter case the platelets remained responsive to 1 U/mL thrombin (data not shown), indicating that the effects of genistein were not caused by toxicity on the permeabilized platelets. Furthermore, the data suggests that thrombin-induced platelet aggregation is associated with multiple intracellular pathways and occurs when both the Tx receptor is blocked and tyrosine phosphorylation is inhibited. Vanadate-induced aggregation of permeabilized platelets was also inhibited by pretreatment with either the cyclo-oxygenase inhibitor aspirin (100 pmol/L; Fig 3A) or the dual cyclo-oxygenase and lipoxygenase inhibitor BW755C (80 Fmol/L; Fig 3B) .
Efects of vanadate on platelet ultrastructure. Electronmicroscopic examination showed that saponin-permeabilized platelets retain a homogeneous distribution of their organelles (Fig 4A) . The addition of vanadate caused the platelets to extend pseudopods, centralize and evacuate their granules, and form small aggregates (Fig 4B) .
Vanadate (100 pmol/L) stimulated the formation of [3ZP]-phosphatidic acid in permeabilized platelets prelabeled with [32P]-orthophosphate (Fig 5, A and B) . This formation of [32P]-phosphatidic acid was inhibited by preincubation with aspirin (100 pmol/ L) (Fig 5B) .
Vanadate ( 100 pmol/L) caused the phosphorylation of platelet proteins, notably of pleckstrin (an index of protein kinase C activity) and, to a variable extent, of myosin light chain (an index of
Efects of vanadate on phospholipase C.
Efects of vanadate on protein phosphorylation.
For personal use only. on November 11, 2017. by guest www.bloodjournal.org From myosin light chain (MLC) kinase activity) (Fig 6A) . This phosphorylation, believed to be on threonine and serine residues, was inhibited by aspirin (Fig 6B) .
Western blotting with the antiphosphotyrosine antibody 4GIO indicates the enhanced presence of proteins of a p proximate molecular weights 29, 32,40,42, and 80 Kd (Fig  7) and the appearance of two faint proteins of molecular weights 26 and 90 Kd (Fig 7) (Fig 8) .
Efects of vanadate on arachidonate metabolism.
DISCUSSION
The present study has extended previous reports of the stimulatory effects of vanadate in human platelet^.'^"^ Vanadate stimulates platelet aggregation in a concentrationdependent manner, and this effect was mediated by the liberation of arachidonic acid and its subsequent conversion to Tx.
Vanadate is known to affect Na+/K+ ATP-: ' GTPbinding protein^,)^ and PTPases.'o Several lines of evidence in the present study indicate that inhibition of PTPases is associated with the stimulation of platelet aggregation. Under the conditions used (ie, cytosolic potassium buffer), the sodium and potassium gradients are lost and vanadate was still able to elicit a response. In addition, the cardiac glycoside ouabain, a known inhibitor of Na+/K+ ATPases, was unable to mimic the stimulatory effects of vanadate. The relevance of inhibition of platelet Na'/K' ATPases is questionable, as platelet activation occurs in the absence of the depolari~a t i o n~~.~~ that would accompany such an inhibition. The concentration of vanadate required to cause aggregation of permeabilized platelets is consistent with that required to inhibit PTPases in platelet lysatesI4 but IO-fold lower than affects GTP-binding protein^.^' Furthermore, vanadate caused the phosphorylation of several phosphotyrosines identified by Western blotting.
One major question addressed by the present study is the site of action of vanadate and, by implication, the role of phosphotyrosine phosphorylation in platelet activation. The vanadate-induced platelet aggregation was associated with the stimulation of phospholipase C (as monitored by the for- mation of phosphatidic acid), protein kinase C (as monitored by the phosphorylation of pleckstrin), myosin light chain kinase (as monitored by the phosphorylation of MLC), and the formation of TxA2. Aggregation, phospholipase C stimulation, and protein phosphorylation were all attenuated by the cyclo-oxygenase inhibitor aspirin. In addition, aggregation wasalso inhibited by BW755C, which is known to selectively inhibit both cyclo-oxygenase and lipoxygenase without affecting pho~pholipases.'~"~ The stimulation of platelets by TxAz leads to the activation of phospholipase C?.4' and s u b sequently MLC kinase and protein kinase C.4IA2 These results show that the activation of phospholipase C and protein phosphorylation are secondary to a phosphotyrosine regulation ofTx production (Fig 9) . Consistent with this, BW755C inhibited TxB2 production but did not affect vanadate-induced arachidonic acid liberation, showing a primary effect of vanadate to promote arachidonic acid release from platelet phospholipids (Fig 9) . Immunoblot analysis indicated that vanadate caused tyrosine phosphorylation of several proteins. These proteins fall into two classes: those of approximate molecular weight 26,29,32,40, and 42 Kd, the phosphorylation of which was attenuated by BW755C; and those ofapproximate molecular weights of 80 and 90 Kd. which were less affected by inhibition of cyclo-oxygenase. The results show that the latter group of phosphotyrosines is associated with the liberation of arachidonic acid (phosphotyrosine[s] a in Fig 9) , whereas the former group is involved at some later stage in the aggregation process (phosphotyrosine[s] b in Fig 9) . This is consistent with the observation that aspirin does not affect tyrosine phosphory- Genistein, a tyrosine kinase inhibitor," blocked the effects of vanadate on platelets. However, genistein has also been shown to antagonize the TxA2 receptor,"." an effect that would also inhibit TxAfmediated vanadate-induced platelet activation.
The possible regulation of neutrophil phospholipase A2, the principle enzyme involved in arachidonic acid release, by a phosphotyrosine was recently hypothesized. 46 The present data supports such a role for a phosphotyrosine, which is regulated by a vanadate-sensitive PTPase, in stimulated human platelets. ported to be endogenous regulators of the enzyme:' although these effects may be caused by an interaction with phospholipids rather than a direct effect on phospholipase A2?* Calpactins are tyrosine ph~sphorylated~~ and it could be postulated that they are potential substrates for the vanadatesensitive PTPase resulting in the liberation of arachidonic acid. The intracellular calcium concentration is also believed to regulate phospholipase A2 activity, although calcium alone does not appear to be sufficient to liberate arachidonic acid. 50 The calcium ionophore A23 I87 has been reported to cause tyrosine phosphorylation5' and there appears to be a particularly complex relationship between calcium and tyrosine pho~phorylation.~~ It is also possible that phosphotyrosine plays a role in transducing the signal across the plasma membrane. There are similarities between vanadate-induced and low-dose collagen-induced platelet aggregation. In both cases platelet aggregation and phospholipase C activation are, to a large degree, TxA2
The link between the collagen receptor and arachidonic acid release is not well defined. A role for newly formed intracellular histamine in the activation of phospholipase A2 has been It has been reported that intracellular histamine may also be related to tyrosine kinase activity in human platelets."
Collagen-induced phospholipase A2 activity has been associated with cytoskeletal assembly in platelets56 and, after platelet activation, the glycoprotein (GP) Ilb/llla complex becomes associated with the cytoskelet~n.~~*~* Tyrosine phosphorylation and GPllb/llIa-mediated aggregation have been intimately associated59 and it is possible that the GPllb/ Illa-induced tyrosine phosphorylation occurs within the cytoskeleton of activated platelets and serves to regulate phospholipase A2. Furthermore, the tyrosine kinase p p 6 P isalso known to be cytoskeletal associated.60 DAQ $. For personal use only. on November 11, 2017 . by guest www.bloodjournal.org From
The combination of orthovanadate and H202 has been reported to stimulate platelet activation, albeit after a considerable lag phase, independently of Tx production." This may reflect differences in the method of administration of the vanadate; saponin-permeabilization versus the combination of vanadate and H2O2. Both processes may have inherent difficulties in interpretation as both saponin and H202 may have detrimental effects on the cell membrane, although under the permeabilization conditions used in the present study little cell damage has been observed.2'.6' Alternatively, the discrepancy may indicate that phospholipase A2 activity and Tx generation is critical in the saponin-permeabilized system, reflecting the substantially lower elevation of cytosolic calcium levels achieved after stimulation. Regardless of the method of administration, vanadate clearly stimulates platelet activation and presents evidence for a role for phosphotyrosine in this process.
In conclusion, the present study shows that vanadate-induced platelet aggregation is mediated by TxA2, the production of which is associated with an inhibition of PTPase activity. This is the first evidence for the regulation of arachidonic acid release by a phosphotyrosine in human platelets. The phosphoprotein is potentially of 80 or 90 Kd that may be a form of phospholipase A2 or some regulatory protein. This further emphasizes both the complex nature of arachidonic acid release from human platelets and the crucial role that phosphotyrosines play in signal transduction in nonproliferative cells.
